ICTP as a Prognostic Indicator in Multiple Myeloma
Author Information
Author(s): I. Elomaa, P. Virkkunen, L. Risteli, J. Risteli
Primary Institution: University of Helsinki; University of Oulu
Hypothesis
Are serum concentrations of ICTP and PICP useful markers for following bone turnover and evaluating treatment response in multiple myeloma?
Conclusion
ICTP is a specific and sensitive marker for bone resorption and can help evaluate treatment response in multiple myeloma.
Supporting Evidence
- ICTP concentration was permanently elevated in nonresponders despite treatment.
- Responders showed a return of ICTP levels to the reference interval during treatment.
- There was a strong correlation between the extent of bone lesions and ICTP levels.
Takeaway
Doctors can use a blood test to check a special marker called ICTP to see how well treatment is working for patients with a type of blood cancer called multiple myeloma.
Methodology
Fifteen patients with untreated multiple myeloma were studied, and serum samples for PICP and ICTP were collected before each treatment course.
Limitations
The study had a small sample size and was preliminary in nature.
Participant Demographics
15 patients (6 females, 9 males, mean age 59 years, range 33-80 years) with untreated multiple myeloma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website